Quidelortho CORP Form 4 insider transactions

Director Edward L. Michael amends his Form 4 filing to include the grant of Converted and Premium Restricted Stock Units (RSUs) received in lieu of cash payments for board service-related fees.

Kenneth F. Buechler, a director at QuidelOrtho Corp, amended a previous filing to include the grant of restricted stock units (RSUs) received in lieu of cash payments.

The Carlyle Group executed multiple sales of QuidelOrtho Corp (QDEL) common stock between August 7th and August 8th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Carlyle Group continues to reduce its stake in QuidelOrtho Corp, selling shares under a pre-arranged Rule 10b5-1 trading plan.

The Carlyle Group executed multiple sales of QuidelOrtho Corp (QDEL) common stock between August 1st and 2nd, 2024, under a pre-arranged Rule 10b5-1 trading plan.

The Carlyle Group executed multiple sales of QuidelOrtho Corp (QDEL) common stock on July 30 and 31, 2024, under a pre-arranged Rule 10b5-1 trading plan.

SVP of Research & Development at QuidelOrtho Corp, Werner Kroll, reports the vesting of restricted stock units and subsequent tax withholding.

The Carlyle Group Inc. reports the sale of QuidelOrtho Corp shares across multiple transactions executed between July 26 and July 29, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Carlyle Group Inc. reports the sale of QuidelOrtho Corp shares across multiple transactions on July 24 and 25, 2024, executed under a pre-arranged Rule 10b5-1 trading plan.

The Carlyle Group executed multiple sales of QuidelOrtho Corp (QDEL) common stock between July 22 and July 23, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Kenneth J. Widder exercised stock options to acquire 3,333 shares of QuidelOrtho Corp at $27.91 on July 19, 2024, and now holds 28,472 shares.

The Carlyle Group continues to reduce its stake in QuidelOrtho Corp (QDEL) through a series of sales executed under a pre-arranged Rule 10b5-1 trading plan.

The Carlyle Group continues to reduce its stake in QuidelOrtho Corp through a series of sales executed under a pre-arranged Rule 10b5-1 trading plan.

The Carlyle Group continues to reduce its stake in QuidelOrtho Corp through a series of sales executed under a pre-arranged Rule 10b5-1 trading plan.

The Carlyle Group executed multiple sales of QuidelOrtho Corp shares between July 10 and July 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Carlyle Group, a major shareholder of QuidelOrtho Corp, executed multiple sales of common stock between July 8th and July 9th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

The Carlyle Group executed multiple sales of QuidelOrtho Corp (QDEL) common stock between July 3rd and July 5th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Carlyle Group Inc. reports the sale of QuidelOrtho Corp shares across multiple transactions on July 1st and 2nd, 2024, executed under a pre-arranged Rule 10b5-1 trading plan.

Chief Financial Officer Joseph M. Busky's stock options were amended to remove performance conditions and vest fully on December 31, 2023, subject to continued service.

The Carlyle Group continues to execute its pre-arranged stock sale plan in QuidelOrtho Corp, disposing of shares at weighted average prices ranging from approximately $32.71 to $33.80.

Carlyle Group continues to reduce its stake in QuidelOrtho Corp through a pre-arranged Rule 10b5-1 trading plan.

The Carlyle Group continues to reduce its stake in QuidelOrtho Corp, selling shares through a pre-arranged 10b5-1 trading plan.

The Carlyle Group executed multiple sales of QuidelOrtho Corp (QDEL) common stock between June 18 and June 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

The Carlyle Group continues to reduce its stake in QuidelOrtho Corp, selling shares through a pre-arranged Rule 10b5-1 trading plan.

The Carlyle Group Inc. reports the sale of QuidelOrtho Corp shares between June 12 and June 13, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Ann D. Rhoads reports the release of restricted stock units and subsequent conversion to common stock.

EVP & CCO Michael S. Iskra reports the release of restricted stock units and subsequent tax withholding of common shares.

QuidelOrtho's CFO, Joseph M. Busky, reports the vesting and subsequent tax-related disposition of common stock.

Director James Prutow reports the release of restricted stock units into common stock on May 28, 2024.

Michelle Hodges, SVP, General Counsel of QuidelOrtho Corp, reports the release of restricted stock units and subsequent tax withholding of common shares.